» Articles » PMID: 2350530

The Effect of Food and Bile Acid Administration on the Relative Bioavailability of Cyclosporin

Overview
Specialty Pharmacology
Date 1990 May 1
PMID 2350530
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

1. The relative bioavailability of cyclosporin was studied in 11 healthy volunteers after single oral capsule doses of cyclosporin on three separate occasions; fasting, with breakfast and with breakfast together with bile acid tablets (400 mg of cholic acid and 100 mg of dehydrocholic acid). 2. There was a significant increase in the area under the blood concentration vs time curve (AUC) of cyclosporin when the drug was taken together with breakfast and bile acid tablets (9078 ng ml-1 h) as compared with breakfast alone (7453 ng ml-1 h, P less than 0.05) or fasting conditions (7283 ng ml-1 h, P less than 0.01). 3. A blood drug concentration vs time curve displaying two peaks was present in 9/11 subjects when cyclosporin was taken with breakfast or with breakfast and bile acid tablets, but only one peak was present when cyclosporin was taken during fasting, suggesting an enterohepatic circulation of cyclosporin or a second absorption phase after the meal. 4. In a separate study, 12 h trough blood cyclosporin concentrations were measured before and after 1 week of bile acid treatment in 19 clinically stable, out-patient transplant recipients who were treated with oral cyclosporin solution (mean dose 2.0 mg kg-1 twice daily). The administration of cyclosporin was not standardized with regard to food intake. There was no significant difference in the blood concentrations of cyclosporin before and after bile acid treatment (114 +/- 38 ng ml-1 vs 121 +/- 38 ng ml-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Effect of hypoalbuminemia on drug pharmacokinetics.

Idasiak-Piechocka I, Lewandowski D, Swigut W, Kalinowski J, Mikosza K, Suchowiejski P Front Pharmacol. 2025; 16:1546465.

PMID: 40051558 PMC: 11882431. DOI: 10.3389/fphar.2025.1546465.


Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles.

Pavlovic N, Golocorbin-Kon S, anic M, Stanimirov B, Al-Salami H, Stankov K Front Pharmacol. 2018; 9:1283.

PMID: 30467479 PMC: 6237018. DOI: 10.3389/fphar.2018.01283.


A Review of Food-Drug Interactions on Oral Drug Absorption.

Deng J, Zhu X, Chen Z, Fan C, Kwan H, Wong C Drugs. 2017; 77(17):1833-1855.

PMID: 29076109 DOI: 10.1007/s40265-017-0832-z.


Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine.

Selby-Pham S, Miller R, Howell K, Dunshea F, Bennett L Sci Rep. 2017; 7(1):1931.

PMID: 28512322 PMC: 5434065. DOI: 10.1038/s41598-017-01888-w.


Gene co-expression network analysis identifies porcine genes associated with variation in metabolizing fenbendazole and flunixin meglumine in the liver.

Howard J, Ashwell M, Baynes R, Brooks J, Yeatts J, Maltecca C Sci Rep. 2017; 7(1):1357.

PMID: 28465592 PMC: 5430975. DOI: 10.1038/s41598-017-01526-5.


References
1.
Quesniaux V, Tees R, SCHREIER M, Wenger R, Donatsch P, Van Regenmortel M . Monoclonal antibodies to ciclosporin. Prog Allergy. 1986; 38:108-22. View

2.
Rogerson M, Marsden J, Reid K, Bewick M, Holt D . Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation. 1986; 41(2):276-8. View

3.
Quesniaux V, Tees R, SCHREIER M, Maurer G, Van Regenmortel M . Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine. Clin Chem. 1987; 33(1):32-7. View

4.
Grevel J, Nuesch E, Abisch E, Kutz K . Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol. 1986; 31(2):211-6. DOI: 10.1007/BF00606661. View

5.
Shibata N, Minouchi T, Hayashi Y, Ono T, Shimakawa H . Quantitative determination of cyclosporin A in whole blood and plasma by high performance liquid chromatography. Res Commun Chem Pathol Pharmacol. 1987; 57(2):261-71. View